Copyright © 2020 Elsevier Inc. All rights reserved.
Détails bibliographiques
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 220(2020) vom: 01. Nov., Seite 108598
|
|---|
| Auteur principal: |
Mastellos, Dimitrios C
(Auteur) |
|---|
| Autres auteurs: |
Pires da Silva, Bruno G P,
Fonseca, Benedito A L,
Fonseca, Natasha P,
Auxiliadora-Martins, Maria,
Mastaglio, Sara,
Ruggeri, Annalisa,
Sironi, Marina,
Radermacher, Peter,
Chrysanthopoulou, Akrivi,
Skendros, Panagiotis,
Ritis, Konstantinos,
Manfra, Ilenia,
Iacobelli, Simona,
Huber-Lang, Markus,
Nilsson, Bo,
Yancopoulou, Despina,
Connolly, E Sander,
Garlanda, Cecilia,
Ciceri, Fabio,
Risitano, Antonio M,
Calado, Rodrigo T,
Lambris, John D |
|---|
| Format: | Article en ligne
|
|---|
| Langue: | English |
|---|
| Publié: |
2020
|
|---|
| Accès à la collection: | Clinical immunology (Orlando, Fla.)
|
|---|
| Sujets: | Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
AMY-101
Biomarkers
C3 inhibition
C5 blockade
COVID-19
Drug efficacy
Eculizumab
plus...
Thromboinflammation
Antibodies, Monoclonal, Humanized
C3 protein, human
Complement C3
Complement C5
Complement Inactivating Agents
IL6 protein, human
Immunologic Factors
Interleukin-6
Peptides, Cyclic
compstatin
C-Reactive Protein
9007-41-4
eculizumab
A3ULP0F556 |
|---|